Intra-Cellular Therapies Announces Presentation of Lumateperone Long-term Open Label Safety Study at the 2019 Congress of the ...
NEW YORK, April 09, 2019 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced plans to present analyses from its …